TABLE 3.

Risk factors for adverse effects of sulfasalazine (SASP) in the treatment of inflammatory bowel disease

	Overall adverse effects		Serum SP dose-related adverse effects
Risk factors	With adverse effects	Without adverse effects	With adverse effects	Without adverse effects
Male/female, n	33/24	5/6	33/24	3/6
Age, years (mean ± SD)	39.19±11.74	42.36±17.81	39.19±11.74	44.78±18.38
SASP dose (mean ± SD)	2.92±0.82	2.55±0.68	2.92±0.82	2.55±0.72
Treatment time, months (mean ± SD)	13.00±8.52	16.73±7.54	13.00±8.52	16.67±7.66
Fast/slow acetylator genotypes, n	48/9	6/5*	48/9	4/5†

^*36% versus 11%, OR of 0.26, 95% CI 0.065 to 1.004, P=0.051;

^†36% versus 8%, OR of 0.17, 95% CI 0.039 to 0.749, P=0.019. SP Sulfapyridine